Androgen insensitivity

被引:0
作者
Gottlieb, B
Pinsky, L
Beitel, LK
Trifiro, M
机构
[1] Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Mol Endocrinol Lab, Montreal, PQ H3T 2E1, Canada
[2] John Abbott Coll, Montreal, PQ, Canada
[3] McGill Univ, Montreal, PQ H3A 2T5, Canada
来源
AMERICAN JOURNAL OF MEDICAL GENETICS | 1999年 / 89卷 / 04期
关键词
androgen insensitivity; androgen receptor; gene mutations; pharmacotherapy;
D O I
10.1002/(SICI)1096-8628(19991229)89:4<210::AID-AJMG5>3.0.CO;2-P
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The androgen receptor (AR) protein regulates transcription of certain genes. Usually, this activity depends upon a central DNA-binding domain that permits the binding of androgen-AR complexes to regulatory DNA sequences near or in a target gene. The AR also has a C-terminal androgen-binding domain (ABD) and an N-terminal modulatory domain. These domains interact among themselves and with coregulatory, nonreceptor proteins to determine vector control over a gene's transcription rate. The precise roles of these proteins are active research areas. Severe X-linked androgen receptor gene (AR) mutations cause complete androgen insensitivity, mild ones impair virilization with or without infertility, and moderate ones sometimes yield a wide phenotypic spectrum among sibs. Different expressivity may reflect variability of AR-interactive proteins. The family history must identify heterozygous XX females with sparse, delayed, or asymmetric pubic/axillary hair or delayed menarche and infertile XY maternal aunts or uncles, Mutation type and density vary along the length of the AR. N-terminal polyglutamine tract expansion limits AR transactivation, causing a form of mild androgen insensitivity. Analysis of ABD mutations that do not impair androgen binding or impair it selectively will illuminate its intradomain properties. For partial androgen Insensitivity and mild androgen insensitivity, pharmacotherapy with certain androgens or other steroids may overcome some dysfunction of certain mutant ARs. Experience with this approach is limited; outcomes have been generally disappointing. (C) 2000 Wiley-Liss, Inc.
引用
收藏
页码:210 / 217
页数:8
相关论文
共 48 条
[1]   Rethinking genotype and phenotype correlations in polyglutamine expansion disorders [J].
Andrew, SE ;
Goldberg, YP ;
Hayden, MR .
HUMAN MOLECULAR GENETICS, 1997, 6 (12) :2005-2010
[2]  
BEITEL LK, 1998, ANAL TRIPLET REPEATD
[3]  
Boehmer ALM, 1997, AM J HUM GENET, V60, P1003
[4]   Characterization of an expanded glutamine repeat androgen receptor in a neuronal cell culture system [J].
Brooks, BP ;
Paulson, HL ;
Merry, DE ;
SalazarGrueso, EF ;
Brinkmann, AO ;
Wilson, EM ;
Fischbeck, KH .
NEUROBIOLOGY OF DISEASE, 1997, 3 (04) :313-323
[5]   THE LENGTH AND LOCATION OF CAG TRINUCLEOTIDE REPEATS IN THE ANDROGEN RECEPTOR N-TERMINAL DOMAIN AFFECT TRANSACTIVATION FUNCTION [J].
CHAMBERLAIN, NL ;
DRIVER, ED ;
MIESFELD, RL .
NUCLEIC ACIDS RESEARCH, 1994, 22 (15) :3181-3186
[6]   Delineation of two distinct type I activation functions in the androgen receptor amino-terminal domain [J].
Chamberlain, NL ;
Whitacre, DC ;
Miesfeld, RL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (43) :26772-26778
[7]   Reduced androgen receptor gene expression with first exon CAG repeat expansion [J].
Choong, CS ;
Kemppainen, JA ;
Zhou, ZX ;
Wilson, EM .
MOLECULAR ENDOCRINOLOGY, 1996, 10 (12) :1527-1535
[8]   MUTANT ANDROGEN RECEPTOR DETECTED IN AN ADVANCED-STAGE PROSTATIC-CARCINOMA IS ACTIVATED BY ADRENAL ANDROGENS AND PROGESTERONE [J].
CULIG, Z ;
HOBISCH, A ;
CRONAUER, MV ;
CATO, ACB ;
HITTMAIR, A ;
RADMAYR, C ;
EBERLE, J ;
BARTSCH, G ;
KLOCKER, H .
MOLECULAR ENDOCRINOLOGY, 1993, 7 (12) :1541-1550
[9]  
CUNDY TF, 1986, FERTIL STERIL, V46, P721
[10]  
Gottlieb B, 1999, HUM MUTAT, V14, P103, DOI 10.1002/(SICI)1098-1004(1999)14:2<103::AID-HUMU2>3.3.CO